These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19996086)
1. Mao-B inhibitor know-how: back to the pharm. Burke WJ Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086 [No Abstract] [Full Text] [Related]
2. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
3. [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease]. Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(9):91-6. PubMed ID: 19004128 [No Abstract] [Full Text] [Related]
5. Rasagiline (Azilect) for Parkinson's disease. Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358 [No Abstract] [Full Text] [Related]
6. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
7. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
8. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138 [No Abstract] [Full Text] [Related]
9. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. Unzeta M; Sanz E Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Tabakman R; Lecht S; Lazarovici P Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044 [TBL] [Abstract][Full Text] [Related]
11. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Bainbridge JL; Page RL; Ruscin JM Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444 [TBL] [Abstract][Full Text] [Related]
12. Selective MAO-B inhibitors have low potential for the tyramine effect. Isaacson SH Mov Disord; 2010 Jan; 25(1):123-4. PubMed ID: 19006188 [No Abstract] [Full Text] [Related]
13. Present and future drug treatment for Parkinson's disease. Schapira AH J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1472-8. PubMed ID: 16227533 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen JJ; Swope DM J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398 [TBL] [Abstract][Full Text] [Related]
16. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
17. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related]
18. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Matos MJ; Viña D; Picciau C; Orallo F; Santana L; Uriarte E Bioorg Med Chem Lett; 2009 Sep; 19(17):5053-5. PubMed ID: 19628387 [TBL] [Abstract][Full Text] [Related]
19. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. Müller T; Riederer P; Grünblatt E Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929 [TBL] [Abstract][Full Text] [Related]